5,410 Shares in Novo Nordisk A/S $NVO Acquired by Capital Management Associates Inc

Key Points

• Capital Management Associates Inc has acquired a stake of 5,410 shares in Novo Nordisk A/S valued at approximately $373,000 during the second quarter.
• Wall Street analysts have mixed ratings for Novo Nordisk A/S, with recent downgrades, while the stock maintains a consensus target price of $77.50.
• Novo Nordisk A/S reported $0.97 earnings per share for the last quarter, exceeding analysts' expectations, and has announced a semi-annual dividend of $0.4119 per share.

Capital Management Associates Inc bought a new stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 5,410 shares of the company's stock, valued at approximately $373,000.

A number of other large investors have also recently bought and sold shares of NVO. First Hawaiian Bank boosted its holdings in shares of Novo Nordisk A/S by 0.6% during the first quarter. First Hawaiian Bank now owns 22,401 shares of the company's stock worth $1,556,000 after purchasing an additional 142 shares during the last quarter. Anchor Investment Management LLC boosted its holdings in shares of Novo Nordisk A/S by 1.1% during the first quarter. Anchor Investment Management LLC now owns 13,597 shares of the company's stock worth $944,000 after purchasing an additional 150 shares during the last quarter. Xponance Inc. raised its position in shares of Novo Nordisk A/S by 5.0% in the 1st quarter. Xponance Inc. now owns 3,314 shares of the company's stock worth $230,000 after buying an additional 158 shares during the period. Foster Dykema Cabot & Partners LLC raised its position in shares of Novo Nordisk A/S by 3.8% in the 1st quarter. Foster Dykema Cabot & Partners LLC now owns 4,526 shares of the company's stock worth $319,000 after buying an additional 166 shares during the period. Finally, PFG Investments LLC raised its position in shares of Novo Nordisk A/S by 1.0% in the 1st quarter. PFG Investments LLC now owns 18,102 shares of the company's stock worth $1,257,000 after buying an additional 178 shares during the period. Institutional investors and hedge funds own 11.54% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on NVO. UBS Group lowered Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research report on Tuesday, August 5th. TD Cowen cut their target price on Novo Nordisk A/S from $105.00 to $70.00 and set a "buy" rating on the stock in a research report on Tuesday, August 19th. Wall Street Zen lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Barclays reaffirmed an "equal weight" rating on shares of Novo Nordisk A/S in a research report on Wednesday, July 30th. Finally, BNP Paribas Exane raised Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 target price on the stock in a research report on Wednesday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S currently has an average rating of "Moderate Buy" and a consensus target price of $77.50.

Novo Nordisk A/S Stock Up 1.0%

Shares of NYSE NVO opened at $59.63 on Thursday. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $120.56. The firm has a market cap of $266.25 billion, a price-to-earnings ratio of 16.38, a PEG ratio of 2.64 and a beta of 0.68. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. The stock's 50-day simple moving average is $55.03 and its 200-day simple moving average is $63.45.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The business had revenue of $11.69 billion for the quarter, compared to analyst estimates of $77.51 billion. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were given a dividend of $0.4119 per share. This represents a dividend yield of 240.0%. The ex-dividend date of this dividend was Monday, August 18th. Novo Nordisk A/S's payout ratio is presently 22.53%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.